Study of Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V)

The research company LimmaTech Biologics AG is conducting the clinical trial Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V).

In this study, the tetravalent bioconjugate candidate vaccine Kleb4V will be tested to obtain first-time-in-human (FTIH) data on its safety and immunogenicity in healthy adults.

It is planned to include 166 participants.

Actual study start date is July 5, 2021. The researchers expect to complete the study by June 2022.

One primary outcome measure is Immunogenicity: IgG (Immunoglobulin G) titers against the Klebsiella pneumoniae O serotypes included in the vaccine, For each active group vs. placebo: Comparison of geometric mean titers (GMTs) of serum IgG against the four K. pneumoniae O-serotypes included in Kleb4V.

Further details about this study may be found here:

Clinical Research News

Upcoming Clinical Trials